Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic


San Diego, California, October 5, 2016  --  Neuropore Therapies, Inc. (NPTTM) has published a report in the journal Brain describing the discovery and characterization of a small molecule compound, NPTTM100-18A that directly targets α-synuclein and produces beneficial effects in an animal model of Parkinson’s disease. Abnormal accumulation and propagation of the neuronal protein α-synuclein has been hypothesized to underlie the pathogenesis of Parkinson’s disease, and other synucleinopathies.


The report entitled, “A De Novo Compound Targeting Alpha-Synuclein Improves Deficits In Models of Parkinson’s Disease” describes findings supporting the hypothesis that NPTTM100-18A reduces α-synuclein toxicity through a novel mechanism that involves displacing pathological α-synuclein from the membrane. In vivo evaluations in three different animal models of Parkinson’s disease demonstrated beneficial effects of NPTTM100-18A treatment on measures of neuropathology (α-synuclein levels, inflammation, and markers of neuronal health) and behavior.


“The results of this effort between Neuropore and academic collaborators at UCSD, UCLA and the University of Vienna has provided key evidence to support the notion that clearing aggregation-prone α-synuclein from cell membranes is a feasible therapeutic approach for developing disease-modifying treatments of Parkinson’s disease and other synucleinopathies,” said Douglas Bonhaus, Chief Operations Officer at Neuropore.  


The report can be downloaded at:


Media and Investor Contact:


Douglas Bonhaus, COO

(858) 273-1831